Lonza and Moderna shoot for billion COVID-19 vaccine doses

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Oatawa)
(Image: Getty/Oatawa)

Related tags: Lonza, Moderna, COVID-19, Coronavirus, Vaccine, mRNA

Moderna announces it has partnered with Lonza with the aim of producing one billion doses annually.

Moderna’s mRNA vaccine candidate for COVID-19 was the first to be administered in humans, after a development time of just 63 days​.

Now, with funding​ from the US Biomedical Advanced Research and Development Authority (BARDA), Moderna is working to rapidly scale its manufacturing capability of the potential vaccine.

The company announced that it had signed a 10-year worldwide partnership with Lonza, a contract development and manufacturing organization (CDMO), for the large-scale manufacture of mRNA-1273.

Additionally, Moderna noted that Lonza would also be responsible for the manufacture of further products ‘in the future’.

The plan is to begin technology transfer for manufacture in June, which should enable the first batches of the vaccine to be produced in July by Lonza’s US business.

After this step is complete, the partners will be able to assess taking on additional production suites across Lonza’s worldwide network, with the long-term goal of reaching 1 billion doses per year.

Lonza stated that manufacturing suites in Switzerland will be made available for the production of mRNA-1273.

Moderna will utilize its own manufacturing capabilities in the US for the vaccine candidate, and the company added that it would still be looking to ‘ramp up’ its capacity for clinical development and potential commercialization.

The partnership aiming to hit capacity for one billion doses follows a similar path to Johnson & Johnson’s vaccine candidate; J&J also stated that it aimed to enlarge capacity to hit the same figure, signing a partnership with Catalent​ last week, among other partners, to achieve this.

Despite the speed with which vaccine candidates, and their related partnerships, are developing, there remains doubt as to whether it will be possible to see one reach commercialization in the next year, according to an analyst at GlobalData​.

Related news

Show more

Related products

show more

Liposomal and Nanoparticle Technology

Liposomal and Nanoparticle Technology

Pfizer CentreOne | 18-Nov-2022 | Technical / White Paper

Medical science is continuously searching for better ways to administer drugs into the body and to maximize the therapeutic effectiveness of the drugs...

GMP manufacturing of buffers and liquid blends

GMP manufacturing of buffers and liquid blends

Actylis – The Partner of Choice | 16-Nov-2022 | Technical / White Paper

Actylis manufactures buffers, process solutions, cleaning solutions, Water for Injection (WFI) for further processing, and custom liquid blends in compliance...

Custom manufacturing of protease inhibitor PMSF

Custom manufacturing of protease inhibitor PMSF

Actylis – The Partner of Choice | 09-Nov-2022 | Technical / White Paper

By combining 75+ years of manufacturing and sourcing expertise, Actylis provides a wide portfolio of GMP ingredients to the pharma & biopharma market,...

Related suppliers

Follow us


View more